Repurposing Drugs for Alzheimer's Disease: Cathepsin B Inhibitors
Author Information
Author(s): Alrouji Mohammed, Yasmin Sabina, Alshammari Mohammed S., Alhumaydhi Fahad A., Sharaf Sharaf E., Shahwan Moyad, Shamsi Anas
Primary Institution: King Khalid University
Hypothesis
Can repurposed drugs effectively inhibit Cathepsin B to aid in Alzheimer's disease treatment?
Conclusion
Lurasidone and Paliperidone are promising candidates as Cathepsin B inhibitors with potential applications in Alzheimer's disease therapy.
Supporting Evidence
- Lurasidone and Paliperidone showed significant binding affinity for Cathepsin B.
- Both drugs formed stable complexes with Cathepsin B during molecular dynamics simulations.
- The study identified key interactions between the drugs and Cathepsin B that may inhibit its activity.
- Repurposing existing drugs can accelerate the development of new therapies for Alzheimer's disease.
Takeaway
Scientists found that two existing drugs, Lurasidone and Paliperidone, might help treat Alzheimer's disease by blocking a protein called Cathepsin B.
Methodology
The study used virtual screening of repurposed drugs from the DrugBank database and molecular dynamics simulations to identify potential CatB inhibitors.
Limitations
The findings are based on in silico analyses, and further in vitro and in vivo studies are necessary to confirm efficacy.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website